Vimarsana
Biggest News Aggregation in the World

Page 4 - Dirk Arnold News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dirk Arnold. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dirk Arnold Today - Breaking & Trending Today

Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027 - Vimarsana News

Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027

/PRNewswire/ -- Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent treatment. Factors...

Financialnewsmedia.com: Gastrointestinal Cancer Treatment Trials Driven by Rising Incidences of Colorectal Cancer - Vimarsana News

Financialnewsmedia.com: Gastrointestinal Cancer Treatment Trials Driven by Rising Incidences of Colorectal Cancer

- FinancialNewsMedia.com News Commentary - PALM BEACH, Fla., Jan. 20, 2022 /PRNewswire/ -- Despite significant progress in the treatment of gastric cancer, it is still among the leading

Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium - Vimarsana News

Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) provided an enrollment update on the phase 1/2 GOBLET study in a poster presentation at the...

Gastrointestinal Cancer Treatment Trials Driven by Rising Incidences of Colorectal Cancer - Vimarsana News

Gastrointestinal Cancer Treatment Trials Driven by Rising Incidences of Colorectal Cancer

/PRNewswire/ -- Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to cancer, across the world....

Oncolytics Biotech Inc.: Oncolytics Biotech Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium - Vimarsana News

Oncolytics Biotech Inc.: Oncolytics Biotech Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Successfully enrolled first-line metastatic pancreatic and third-line metastatic colorectal safety run-ins Company moving to full enrollment pending independent safety review Multi-center